Adamas Pharmaceuticals (ADMS) Is Weak On High Volume Today
Trade-Ideas LLC identified
(
) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Adamas Pharmaceuticals as such a stock due to the following factors:
- ADMS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $4.1 million.
- ADMS has traded 50,810 shares today.
- ADMS is trading at 2.62 times the normal volume for the stock at this time of day.
- ADMS is trading at a new low 3.03% below yesterday's close.
'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ADMS with the Ticky from Trade-Ideas. See the FREE profile for ADMS NOW at Trade-Ideas
More details on ADMS:
Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. Currently there are 7 analysts that rate Adamas Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Adamas Pharmaceuticals has been 264,000 shares per day over the past 30 days. Adamas has a market cap of $351.2 million and is part of the health care sector and drugs industry. Shares are down 45.2% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Adamas Pharmaceuticals as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Biotechnology industry average. The net income has decreased by 13.3% when compared to the same quarter one year ago, dropping from -$12.20 million to -$13.83 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ADAMAS PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- ADMS's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 39.68%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
- ADAMAS PHARMACEUTICALS INC has improved earnings per share by 5.8% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, ADAMAS PHARMACEUTICALS INC swung to a loss, reporting -$2.86 versus $0.54 in the prior year. For the next year, the market is expecting a contraction of 9.1% in earnings (-$3.12 versus -$2.86).
- The revenue fell significantly faster than the industry average of 20.2%. Since the same quarter one year prior, revenues fell by 22.6%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
- You can view the full Adamas Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.